Sarina Piha Paul, MD
Medical Oncology · Houston, TXNPI 1235381179
Payments from drug & device makers
Across 2,495 payments — averaging $10,407 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$3.8M
- Incyte Corporation$2.6M
- Pfizer$2.5M
- Daiichi Sankyo Inc.$2.3M
- Chugai Pharmaceutical Co., Ltd.$2.1M
- Alkermes, Inc.$1.6M
- plus $11.1M from 20 others
Across 9 payments — averaging $1726.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$12K
- Novartis$3K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 353 | $3,843,790 |
| Incyte Corporation | 678 | $2,582,289 |
| Pfizer | 38 | $2,469,357 |
| Daiichi Sankyo Inc. | 499 | $2,348,903 |
| Chugai Pharmaceutical Co., Ltd. | 191 | $2,080,876 |
| Alkermes, Inc. | 113 | $1,584,691 |
| Seagen Inc. | 168 | $1,529,751 |
| Puma Biotechnology, Inc. | 26 | $1,506,308 |
| Boehringer Ingelheim | 13 | $1,269,946 |
| E.r. Squibb & Sons, L.L.C. | 20 | $1,144,836 |
| GSK | 43 | $945,665 |
| Tesaro, Inc. | 15 | $935,867 |
| Janssen Research & Development, LLC | 31 | $884,745 |
| Eli Lilly | 8 | $679,778 |
| AbbVie | 18 | $573,959 |
| Hoffmann-la Roche Limited | 1 | $415,753 |
| Novartis | 4 | $380,136 |
| Tanabe Pharma America, Inc. | 5 | $251,976 |
| Day One Biopharmaceuticals | 16 | $227,749 |
| AstraZeneca | 2 | $150,432 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 117 | $87,549 |
| Genentech, Inc. | 10 | $44,789 |
| F. Hoffmann-la Roche AG | 2 | $7,944 |
| Gilead | 2 | $6,932 |
| SCS Boehringer Ingelheim Comm.v | 113 | $6,551 |
| Boehringer Ingelheim International GmbH | 9 | $5,698 |
How this compares
$25,966,268 in reported general payments places this provider in the 95th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Houston
- Hagop KantarjianHouston$100.5M
- Timothy YapHouston$56.7M
- Yasir ElaminHouston$41.3M
- David HongHouston$31.6M
- Guillermo Garcia-ManeroHouston$31.6M
- Jason WestinHouston$30.8M
- Lucia MasarovaHouston$29.7M
- Jordi Rodon AhnertHouston$28.1M
- Jenny ChangHouston$17.8M
- Hun LeeHouston$15.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.